Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Dermorphin peptide icon, one bubble per amino acidDermorphin7 residuesYAFGYPSEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Dermorphin

1.3 min half-life·Injection

Also known as: H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, Dermorphine

Thirty to forty times more potent than morphine, and it comes from a frog. Dermorphin (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) is a seven-amino-acid opioid peptide first isolated in 1981 from the skin of South American tree frogs in the genus Phyllomedusa. A 1985 trial in 150 surgical patients found intrathecal dermorphin outlasted intrathecal morphine for postoperative pain [10]. No later pain trial followed. Research interest has remained mostly academic since then. Dermorphin's main notoriety comes from horse-racing doping that surfaced in 2011 and led to 2017 federal convictions. It's an unapproved, unscheduled opioid with lethal overdose potential. It appears here strictly for research reference.

What Is Dermorphin?

Seven amino acids from a tree frog's skin changed opioid pharmacology in 1981. Dermorphin (CAS 77614-16-5; H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) binds mu-opioid receptors with a Kd of 0.46 nM in rat brain [6]. That makes it one of the most potent naturally occurring analgesics ever identified. Vittorio Erspamer's group isolated it from Phyllomedusa sauvagei skin and published its pharmacology in 1981 (Broccardo et al.)[1].

The mechanism is straightforward. A rare D-alanine at position 2 locks the peptide backbone into an ideal shape for mu-receptor activation and blocks enzymatic breakdown. In 1987, Kreil's group found a normal alanine codon at that spot in the precursor gene, which points to a conversion after translation [2]. When administered intrathecally to rodents, dermorphin proved 3,000 to 5,000 times more active than spinal morphine in standard pain assays [3].

In 1985, a double-blind randomized trial in 150 surgical patients compared intrathecal dermorphin with intrathecal morphine and intramuscular pentazocine [10]. Pain relief on dermorphin lasted about 43 hours, against 34 hours on morphine. Small IV studies in healthy volunteers ran from 1983 [11] to 1986 [12]. No later pain trial followed [5].

Dermorphin resurfaced in 2011, but not in a lab. It had been given to racehorses, unseen by standard equine drug screens, until tips from a few North American tracks surfaced that year [4]. In 2017 a federal jury convicted a Louisiana veterinarian and a Nebraska pharmacy of conspiring to sell it to improve race horse performance. ARCI now lists it as Class 1, its most serious tier.

A 2018 review by Keppel Hesselink and Schatman [5] called for new intrathecal trials in postoperative pain and palliative care. No registered trial has followed. No modern clinical program exists. It isn't on the federal controlled substance schedules, and FDA has not approved it for humans or animals.

How Dermorphin Works

Dermorphin targets the mu-opioid receptor (MOR) with a binding affinity of approximately 0.46 nM, confirmed by equilibrium binding studies using tritiated dermorphin in rat brain membranes [6]. Selectivity is about 88-fold for mu over delta and more than 7,000-fold over kappa [6].

Once bound, dermorphin triggers Gi/Go protein coupling. Three downstream effects follow. Adenylyl cyclase gets inhibited, dropping intracellular cAMP. Voltage-gated N-type calcium channels close, cutting neurotransmitter release. Inwardly rectifying potassium channels (GIRKs) open, hyperpolarizing the neuron. Pain signal transmission shuts down at both spinal and supraspinal levels.

The peptide's structure explains its potency. The N-terminal tetrapeptide Tyr-D-Ala-Phe-Gly is the "message" domain, responsible for receptor activation. The C-terminal tripeptide Tyr-Pro-Ser-NH2 is the "address" domain, directing selectivity toward mu-receptors specifically.

Something interesting happens after binding. Dermorphin promotes MOR internalization through beta-arrestin recruitment. When researchers blocked this internalization in rats, the analgesic effect dropped [7]. Receptor trafficking isn't just a cleanup process; it actively contributes to pain relief.

At the systems level, dermorphin modulates descending pain inhibitory pathways from the periaqueductal gray and rostral ventromedial medulla. It amplifies the body's own pain suppression circuits rather than working only at the site of injury.

Dermorphin Benefits

  • Dermorphin benefits center on extreme analgesic potency and pharmacological selectivity, though most data comes from preclinical models, plus a 1985 intrathecal trial and small 1980s IV studies in volunteers.
  • Sub-microgram doses produce full analgesia in rodent models. Intrathecal administration showed 3,000-5,000x the potency of spinal morphine [3].
  • Mu-opioid receptor selectivity is about 88-fold over delta and more than 7,000-fold over kappa in rat brain binding [6]. That precision makes it a clean pharmacological tool for isolating mu-receptor signaling.
  • Tolerance develops more slowly than with morphine at equianalgesic doses in animal models. Naloxone-precipitated withdrawal also appears less intense in preclinical comparisons.
  • The D-Ala2 residue confers enzymatic resistance that endogenous opioid peptides lack. Activity duration extends well beyond what enkephalins or endorphins can achieve.
  • Dermorphin has served as a structural template for designing novel analgesic compounds. Glycodermorphin analogs showed improved blood-brain barrier penetration and prolonged activity [8].
  • A 1985 intrathecal trial in 150 surgical patients found pain relief lasted longer than with intrathecal morphine, about 43 versus 34 hours [10].

Dermorphin: Science vs Community Consensus

Science Only
Scientific Evidence
Weak
Based on 18 key studies·Research only

Potent mu-opioid agonist: 30-40x morphine in isolated-tissue assays, and 752-2,170x by intracerebroventricular injection in rats [1].

Dosing studied: No established human dose. Intrathecal RCT: a 20 mcg dose in surgical patients (PMID 3831962). Volunteer IV studies: 5.5 mcg/kg/min for 30 min (PMID 6833466). Equine study: 9.3 mcg/kg IV or IM (PMID 25376170).
Read the evidence (key study, limitations)

A 1985 RCT in 150 surgical patients found intrathecal dermorphin outlasted intrathecal morphine and IM pentazocine [10]. Small IV studies in volunteers ran in 1983-1986; no later pain trial. No approved human use is known.

Key Study

Broccardo, Erspamer et al. 1981 (PMID 7195758): pharmacological characterization. Basso et al. 1985 (PMID 3831962): intrathecal RCT, 150 surgical patients. Robinson et al. 2015 (PMID 25376170): equine PK. Keppel Hesselink and Schatman 2018 (PMID 30538538): review.

Limitations

One clinical pain RCT (1985, 150 surgical patients, intrathecal); never replicated. No Phase 2/3 trials. The calculator dose tiers have no human source. Other human data are small 1983-1986 IV studies in volunteers on hormones and pain reflexes (PMID 6833466, PMID 3697765). One was placebo-controlled; no human PK study was found. No clinical development since the 1980s.

Community Experience
Weak
2.0/5
Based on <50 Reddit threads total

No documented human self-use protocols in peptide or harm-reduction communities.

Community dosing: No community dosing data exists.
Read the reports (what users report 3, common issues 5)

Community awareness is almost entirely limited to equine doping context. Extreme caution consensus among the few discussions that exist.

What users report (3)
  • Extreme analgesic potency at sub-microgram doses: theoretical interest for refractory pain
  • Slower tolerance development than morphine in animal models: noted by researchers
  • High mu-opioid selectivity: valued as a pharmacological research tool
Common issues (5)
  • No approved human use; equine doping history creates legal and sourcing risk
  • High addiction and physical dependence potential with zero community safety infrastructure
  • Unapproved in the US for humans or animals; a 2017 federal case over sales for race horses ended in convictions
  • No harm-reduction community exists for this compound
  • Zero peer-tested protocols; essentially uncharted territory in human self-administration
Science-Only Evidence

Science-only: published research exists (preclinical + 1 human RCT from 1985) but no community human-use protocols have emerged. The compound occupies a niche as an academic/pharmacological research tool, not a self-use peptide.

Dermorphin Dosage Guide

No established human dose

No human dose has been established for dermorphin, so this page shows no dose tiers. In a 1985 trial of 150 surgical patients, one group got a 20 mcg intrathecal dose for postoperative pain [10]. A 1986 study infused 0.16 mg/kg IV in healthy volunteers to test a pain reflex [12]. Neither one tested a subcutaneous dose.

Note:

Dermorphin is not a self-use peptide. It's listed as a research reference because its pharmacology is genuinely interesting, but the risk profile makes it wholly inappropriate for self-administration.

No human dose has been established. A 1985 trial of 150 surgical patients gave one group 20 mcg intrathecally for postoperative pain [10]. A 1986 study infused 0.16 mg/kg IV in healthy volunteers to test a pain reflex, not to treat pain [12]. Neither one tested a subcutaneous dose. Reconstitution math only: a 1 mg vial with 2 mL bacteriostatic water gives 500 mcg/mL. Each unit on a U-100 insulin syringe then holds 5 mcg. A 2 mg vial with the same 2 mL gives 1,000 mcg/mL, or 10 mcg per unit.

The thing most people miss: plasma half-life (~1.3 min in rodents, ~5.4 min in horses) does not equal duration of action. Receptor binding and beta-arrestin-mediated internalization sustain the analgesic effect for 45-90 minutes IV, and up to 48 hours intrathecally. Don't confuse clearance from blood with clearance from the receptor.

Naloxone on hand is non-negotiable. Analytical-grade sourcing with LC-MS/MS purity verification is also non-negotiable.

Cycling

DEPENDENCE WARNING: Dermorphin should not be used in repeated dosing protocols outside of strictly controlled research settings. Even short-duration repeated exposure carries risk of physical dependence and opioid withdrawal. There is no established or recommended cycling protocol for human use. Any investigational protocol must include naloxone availability and medical supervision. Tolerance to analgesic effects can develop within days of repeated administration.

Dermorphin reconstitution math
Vial and water math with syringe visualization. No preset dose.

Or use the universal Peptide Calculator for any peptide.

How to Inject Dermorphin

  1. 1
    Step 1

    Verify naloxone (0.4-2 mg IV/IM) is immediately accessible before opening the vial. Non-negotiable safety requirement.

  2. 2
    Step 2

    Reconstitute a 1 mg vial of lyophilized dermorphin with 2 mL bacteriostatic water. Gently swirl until dissolved. Do not vortex. This yields 500 mcg/mL, or 5 mcg per unit on a U-100 insulin syringe.

  3. 3
    Step 3

    A 2 mg vial with the same 2 mL yields 1,000 mcg/mL, or 10 mcg per unit. Check which vial you hold before every draw.

  4. 4
    Step 4

    No human dose has been established, and no human study tested a subcutaneous dose, so this guide gives no dose or unit count.

  5. 5
    Step 5

    No human study tested subcutaneous use, so this guide gives no injection steps.

  6. 6
    Step 6

    Continuous pulse oximetry and respiratory rate monitoring required for at least 60 minutes post-administration. SpO2 must stay at or above 95%. Respiratory rate must stay at or above 12 breaths per minute.

  7. 7
    Step 7

    Store reconstituted solution at 2-8 degrees C and use within 7 days. For IV research applications, use within 24 hours. Lyophilized powder stores up to 24 months at -20 degrees C, desiccated, protected from light.

  8. 8
    Step 8

    Handle it as if it were a controlled substance, even though it is unscheduled: locked storage, usage logs, and proper waste disposal.

FOR RESEARCH USE ONLY. No human therapeutic protocol exists.

Mixing your own vial? Use the Dermorphin reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Dermorphin Stacking Protocols

Works With

Avoid

Benzodiazepines (diazepam, clonazepam, alprazolam)

Severe additive CNS and respiratory depression; combination is potentially fatal. Black box warning equivalent.

Do not combine
Other opioid agonists (morphine, fentanyl, oxycodone, tramadol)

Additive mu-opioid receptor activation; compounded respiratory depression and overdose risk.

Do not combine
Alcohol

Potentiates sedation and respiratory depression via CNS depression.

Do not combine
MAO inhibitors (phenelzine, selegiline, tranylcypromine)

Risk of serotonin syndrome and unpredictable potentiation of opioid effects. Contraindicated.

Do not combine
Gabapentinoids (gabapentin, pregabalin)

FDA warning: increased risk of severe respiratory depression when combined with opioids.

Do not combine
Barbiturates and general anesthetics

Additive CNS depression; compounded respiratory risk.

Do not combine

Estimated Cost

Dermorphin Side Effects

Respiratory depression can kill you. That is the primary risk with dermorphin, and its 30-40x morphine potency makes the margin for error vanishingly small. Bolus injection induced apnea in animal models. In any setting where this peptide is handled, naloxone (0.4-2 mg IV) must be within arm's reach.

The full spectrum of mu-opioid agonist effects applies. Profound sedation. Nausea and vomiting. Constipation and reduced gastrointestinal motility. Miosis. Bradycardia. Urinary retention. These are well-characterized opioid effects, but dermorphin's extreme potency compresses the dose-response curve. Small dosing errors produce disproportionate consequences.

Human safety data is almost nonexistent. One 1985 intrathecal trial and no modern pharmacovigilance data. Everything known about dermorphin's side effect profile comes from preclinical animal models and equine pharmacokinetic studies. That's roughly 250 PubMed publications total, with no controlled human dose-finding work.

Physical dependence develops with repeated administration. Preclinical data suggest withdrawal may be less intense than morphine withdrawal at equianalgesic doses, but "less intense opioid withdrawal" is still opioid withdrawal. Symptoms include agitation, muscle pain, insomnia, diarrhea, and autonomic instability. Dependence signs can emerge within days of repeated dosing.

Addiction potential is high. Dermorphin is a potent mu-opioid agonist. Mu-receptor activation drives the reward pathway. Anyone with a history of substance use disorder faces extreme risk. Tolerance to the analgesic effect develops with chronic use, driving dose escalation.

Drug interactions compound every risk listed above. Benzodiazepines combined with dermorphin create severe additive CNS and respiratory depression; that combination can be fatal. The same applies to other opioid agonists, alcohol, barbiturates, and general anesthetics. MAO inhibitors create risk of serotonin syndrome and unpredictable opioid potentiation. Gabapentinoids (gabapentin, pregabalin) carry an FDA warning for increased respiratory depression when combined with opioids.

Contraindications are extensive. Pregnancy and breastfeeding (opioid peptides cross the placental barrier). Respiratory insufficiency or sleep apnea. Severe hepatic impairment. Concurrent MAO inhibitor use. Paralytic ileus. Traumatic brain injury with raised intracranial pressure. Unmonitored settings without naloxone access. Pediatric populations have zero safety data.

Stop immediately and seek emergency care if respiratory rate drops below 12 breaths per minute, SpO2 falls below 95%, or any signs of opioid toxicity appear.

Common Issues & Solutions

No reversal agent present: unacceptable in any research setting: naloxone 0.4–2 mg IV must be immediately accessible before any dermorphin handling.

Confusing plasma half-life (~1.3–5.4 min) with duration of action: receptor binding and internalization extend analgesic effect 45–90 min IV, up to 48 h intrathecal: far beyond plasma clearance.

Assuming "research-only" label = legal to possess: dermorphin isn't federally scheduled, but FDA has not approved it for humans or animals. Selling it for race horses led to 2017 federal convictions; legal risk is substantial.

Repeated dosing producing tolerance/withdrawal: physical dependence can emerge within days; even short repeated-dosing research protocols require dependence monitoring and withdrawal management planning.

Contamination risk: uncertified research-grade dermorphin may contain incorrect peptide, degradation products, or microbial contaminants; LC-MS/MS purity verification is essential.

Ask AI about this page

Ask AI for a second opinion on Dermorphin dosing and side effects

Contraindications

  • Pregnancy and breastfeeding: opioid peptides cross the placental barrier
  • History of substance use disorder or opioid addiction
  • Respiratory insufficiency or compromised airway, including sleep apnea
  • Severe hepatic impairment (reduced peptidase metabolism)
  • Concurrent use of MAO inhibitors
  • Known hypersensitivity to dermorphin or amphibian-derived peptides
  • Paralytic ileus or gastrointestinal obstruction
  • Unmonitored settings without access to naloxone reversal
  • Pediatric populations (no safety data)
  • Traumatic brain injury with elevated intracranial pressure

Drug Interactions

  • Benzodiazepines: severe additive CNS and respiratory depression; potentially fatal combination
  • Other opioid agonists (morphine, fentanyl, oxycodone): additive respiratory depression and overdose risk
  • Alcohol: potentiates sedation and respiratory depression
  • CNS depressants including barbiturates, sedative antihistamines, and general anesthetics
  • MAO inhibitors: risk of serotonin syndrome and unpredictable potentiation of opioid effects
  • Muscle relaxants (baclofen, cyclobenzaprine): enhanced sedation
  • Naloxone and naltrexone: opioid receptor antagonists that reverse dermorphin effects; naloxone required as emergency reversal agent
  • Gabapentinoids (gabapentin, pregabalin): increased risk of respiratory depression when combined with opioids
  • Additive mu-opioid receptor activation; compounded respiratory depression and overdose risk.

Product Quality

Recommended Monitoring

TestWhenTarget
Respiratory rate and SpO2 (pulse oximetry)Continuous during and 60 min post-administration in any research settingSpO2 ≥ 95%; RR ≥ 12 breaths/min
Opioid withdrawal assessment (COWS scale or equivalent)Before and after any repeated-dosing research protocolCOWS score < 5 before next dose cycle
Liver function tests (ALT, AST, bilirubin)Baseline and after any multi-day research protocolNot listed
Naloxone availability verificationBefore every sessionNaloxone 0.4-2 mg IV/IM on hand at all times
Respiratory rate and SpO2 (pulse oximetry)

Primary lethal risk is respiratory depression; mu-opioid agonism at this potency can cause apnea

Opioid withdrawal assessment (COWS scale or equivalent)

Physical dependence can emerge within days of repeated administration

Liver function tests (ALT, AST, bilirubin)

Hepatic peptidase metabolism; monitoring for metabolic burden in extended research contexts

Naloxone availability verification

Emergency reversal agent; must be immediately accessible: non-negotiable safety requirement

Dermorphin Before and After

Minutes 1-5
IV

Rapid onset of analgesia in preclinical models. Peak plasma concentration reached almost immediately after IV administration. Profound mu-opioid receptor activation with measurable antinociceptive response in rodent hot-plate and tail-flick assays.

Minutes 5-30

Sustained analgesic effect despite rapid plasma clearance (t1/2 ~1.3 min), suggesting tissue-level receptor binding persists beyond plasma availability. Respiratory rate depression observed in animal models.

30-90 minutes

Gradual waning of analgesic effect after single-dose administration. Duration of action is longer than plasma half-life due to slow receptor dissociation kinetics and receptor internalization dynamics.

Hours 2-6

Return to baseline nociceptive thresholds after single dose. Complete metabolic clearance from plasma via hepatic and renal peptidase activity.

Days 3-7
repeated dosing

Measurable analgesic tolerance develops with repeated administration in animal models, though onset is slower than with equivalent morphine protocols. Signs of physical dependence may emerge.

What to Expect

Minutes 0-5 (IV/SC): Pain relief hits fast in preclinical models. Peak analgesia arrives within 1-5 minutes after IV administration. Plasma concentration peaks almost immediately. Mu-opioid receptor activation is profound, measurable across standard rodent nociceptive assays (hot plate, tail flick). No human self-use data exists. Respiratory depression, sedation, miosis, and bradycardia have all been observed in animal models during this phase.

Minutes 5-30: Plasma clears quickly (t1/2 roughly 1.3 min rodent, 5.4 min equine). The peptide is gone from blood fast. But tissue-level receptor binding sustains the analgesic effect well beyond plasma availability. Respiratory depression risk is highest in this window. Nausea and reduced GI motility also show up in animal models.

Minutes 30-90: The analgesic effect gradually fades after a single dose. Duration outlasts the plasma half-life because of slow receptor dissociation and beta-arrestin-mediated receptor internalization. The receptor doesn't let go as fast as the blood clears the peptide.

Hours 2-6: Baseline pain thresholds return. Hepatic and renal peptidases complete metabolic clearance. Terminal elimination half-life is approximately 45 minutes IV based on equine data from Robinson and colleagues [9].

Days 3-7 (repeated dosing): This is where dependence becomes the defining concern. Analgesic tolerance develops in animal models, though onset is slower than with equivalent morphine protocols. Physical dependence signs emerge with repeated dosing. Withdrawal on cessation includes agitation, muscle pain, insomnia, diarrhea, and autonomic instability. Even short repeated-dosing protocols require dependence monitoring and withdrawal management planning. No human protocol data exists.

Detailed Timeline: Science vs Community

Minutes 0-5 (IV/SC)
Science

Peak analgesia within 1-5 min IV (preclinical). Plasma Cmax reached almost immediately IV. Profound mu-opioid receptor activation measurable in rodent nociceptive assays (hot plate, tail flick).

Community

No human self-use data available.

Minutes 5-30
Science

Plasma t1/2 ~1.3 min (rodent) / ~5.4 min (equine); tissue-level receptor binding sustains analgesia beyond plasma availability. Respiratory depression risk highest in this window.

Community

No human data.

Minutes 30-90
Science

Gradual return to baseline nociception after single dose. Duration longer than plasma half-life due to slow receptor dissociation and beta-arrestin-mediated internalization dynamics.

Community

No human data.

Hours 2-6
Science

Return to baseline nociceptive thresholds. Hepatic and renal peptidase-mediated metabolic clearance complete. Terminal elimination t1/2 ~45 min IV (equine data).

Community

No human data.

Days 3-7 (repeated dosing)
Science

Measurable analgesic tolerance develops in animal models, though onset is slower than with equivalent morphine protocols. Physical dependence signs emerge with repeated dosing. Naloxone-precipitated withdrawal less intense than morphine at equianalgesic doses in preclinical models.

Community

No human data. This timeline zone is where dependence risk becomes critical.

Pharmacokinetics

Half-Life
1min
Bioavailability
IV: 100%; IM: 47-100% in horses (n = 3, PMID 25376170). That study gave no oral dose.
Tmax
<1 minute IV; ~15-30 minutes IM (equine)
Data Confidence
moderate

Source: Plasma t1/2 ~1.3 min in rats (Negri and Improta 1984, PMID 6522442). In horses after IV dosing, distribution t1/2 ~5.4 min and elimination t1/2 ~46 min (0.09 and 0.76 h; Robinson et al., 2015, PMID 25376170)

Pharmacokinetics: Active Dose Over Time

t½ = ~1.3 min plasma (rats); ~46 min terminal elimination (IV, horses)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
7
Sequence
YAFGYPS
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Dermorphin

  • Opioid receptor pharmacology researchers
  • Neuroscience and pain signaling investigators
  • Analytical chemists developing equine drug detection methods
  • Medicinal chemists studying structure-activity relationships of opioid peptides

Related Peptides

What Changed for Dermorphin

  1. Regulatory

    Corrected Oct 15, 2026: dermorphin's status section no longer calls it a Schedule I analog; it is unscheduled, with no application listed, per Drugs@FDA.

    What this does not mean: The Analogue Act can still reach an unscheduled substance sold for human use. No DEA statement or court ruling applying it to dermorphin was found (eCFR part 1308 and the DEA list, Oct 15, 2026).

    Source: Drugs@FDA (openFDA) search for active ingredient DERMORPHIN: no matches, retrieved Oct 15, 2026 (opens in a new tab) · Saved copy

  2. Regulatory

    Corrected Oct 15, 2026: dermorphin now carries a sourced US status: none listed in Drugs@FDA and no federal schedule, per Drugs@FDA and the DEA list.

    Before: No sourced US status record After: Unapproved in the US; no application in Drugs@FDA; absent from 21 CFR 1308 and the DEA controlled substances list (Aug 27, 2026)

    What this does not mean: Unscheduled does not make it lawful to sell for human use: in 2017 a federal jury convicted a veterinarian and a pharmacy under the Food, Drug, and Cosmetic Act for selling it for race horses.

    Source: Drugs@FDA (openFDA) search for active ingredient DERMORPHIN: no matches, retrieved Oct 15, 2026 (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 7, 202618 Citations

References

  1. [1]Pharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skin (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]D-alanine in the frog skin peptide dermorphin is derived from L-alanine in the precursor (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Spinal action of dermorphin, an extremely potent opioid peptide from frog skin (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Detection, quantification, and identification of dermorphin in equine plasma and urine by LC-MS/MS for doping control (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Characterisation and visualisation of [3H]dermorphin binding to mu opioid receptors in the rat brain (opens in a new tab)PubMed (opens in a new tab)PubMed
  7. [7]Opioid receptor internalization contributes to dermorphin-mediated antinociception (opens in a new tab)PubMed (opens in a new tab)PubMed
  8. [8]Glycodermorphins: opioid peptides with potent and prolonged analgesic activity and enhanced blood-brain barrier penetration (opens in a new tab)PubMed (opens in a new tab)PubMed
  9. [9]Pharmacokinetics and pharmacodynamics of dermorphin in the horse (opens in a new tab)PubMed (opens in a new tab)PubMed
  10. [10]Intrathecal dermorphine in postoperative analgesia (Peptides 1985) (opens in a new tab)PubMed (opens in a new tab)PubMed
  11. [11]Prolactin-releasing activity of dermorphin, a new synthetic potent opiate-like peptide, in normal human subjects (J Clin Endocrinol Metab 1983) (opens in a new tab)PubMed (opens in a new tab)PubMed
  12. [12]Dermorphin inhibits spinal nociceptive flexion reflex in humans (Brain Res 1986) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Up to 24 months at -20°C, desiccated, protected from light
After Reconstitution
Up to 7 days at 2-8°C; use within 24 hours for IV applications
Temperature
-20°C lyophilized; 2-8°C (36-46°F) reconstituted

Frequently Asked Questions

Dermorphin isn't listed in the US Controlled Substances Act schedules (21 CFR 1308). The Federal Analogue Act (21 U.S.C. § 813) reaches unlisted drugs meant for human consumption that are analogues of Schedule I or II drugs. The statute pairs a chemical-structure test with an effect test; in McFadden v. United States (2015) the government accepted, and the Supreme Court assumed, that both must be shown. No DEA statement or court ruling applying it to dermorphin was found. A 2017 federal horse-doping case in Louisiana ended in conspiracy and adulterated or misbranded drug convictions, not a controlled substance charge.

Dermorphin went undetected in horse racing until 2011. Tips from a few North American tracks then pointed to it, and labs built new tests (PMID 23571464). In 2017 a federal jury convicted a Louisiana veterinarian and a Nebraska pharmacy of conspiring to sell it to improve the performance of race horses. ARCI lists it as Class 1, Penalty Class A, its most serious tier.

Yes. A 1985 double-blind randomized trial in 150 surgical patients compared intrathecal dermorphin with intrathecal morphine and intramuscular pentazocine (PMID 3831962). Dermorphin pain relief lasted longest, about 43 hours. Small IV studies in healthy volunteers ran from 1983 to 1986 (PMID 6833466). No pain trial has followed since (PMID 30538538).

Plasma half-life (distribution phase) is very short (~1.3 min rodent / ~5.4 min equine), meaning dermorphin clears from plasma rapidly. But receptor binding at mu-opioid receptors and subsequent receptor internalization via beta-arrestin recruitment sustains the analgesic effect well beyond plasma availability. In the 1985 surgical trial, one intrathecal dose gave pain relief lasting about 43 hours on average (PMID 3831962).

Theoretically, its extreme potency, mu-selectivity, and potentially slower tolerance development are interesting for palliative care (see PMID 30538538). Practically, regulatory, addiction-liability, and commercial hurdles are enormous. No pharmaceutical company has advanced dermorphin into modern clinical development.